Bisoprolol is a long-acting selective beta-1 blocker with the highest beta-1 selectivity among available beta-blockers. Indicated for hypertension, angina, and heart failure.
Also known as: Zebeta
Beta-blocker + non-dihydropyridine CCB: risk of severe bradycardia.
Same mechanism as atenolol + verapamil. Both reduce AV conduction and contractility.
ECG, heart rate.
Severe bradycardia.
Avoid combination. If necessary, monitor ECG.
DailyMed/FDA; EMC-EMC PT
No documented food or drink interactions.
CONTRAINDICATED in decompensated HF.
Stabilise first.
DailyMed/FDA; EMC-EMC PT
CONTRAINDICATED in pregnancy.
CONTRAINDICATED in 3rd trimester.
Avoid during breastfeeding.
Reliable contraception.
DailyMed/FDA; EMC-EMC PT
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Selective beta-1 blocker with the highest selectivity among available beta-blockers. Prolonged action allows once-daily dosing.
Selectively blocks cardiac beta-1 receptors with a beta-1:beta-2 selectivity ratio of 75:1, reducing heart rate and contractility.
Oral bioavailability: >90%. Food does not significantly affect absorption. Tmax: 2-4 hours.
Metabolised ~50% hepatically (CYP3A4) and ~50% renally. No significant genetic polymorphism. Minimal CYP-mediated interactions.
10-12 hours. Elimination: ~50% urine (metabolites and unchanged), ~50% faeces. No adjustment required in hepatic impairment.
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
